Glucotrack, Inc. Announces Pricing of $3 Million Public Offering

Offering details

Glucotrack priced a best-efforts public offering that consists of two security types: 169,388 shares of common stock sold at $2.04 per share and pre-funded warrants exercisable for up to 1,350,220 shares of common stock sold at $2.039 per pre-funded warrant. The company said it expects to receive aggregate gross proceeds of approximately $3,100,000, before deducting placement agent fees and offering expenses. The offering was priced at-the-market under Nasdaq rules and is expected to close on or about September 25, 2026, subject to customary closing conditions.

Sources: S1

Distribution and registration

Dawson James Securities, Inc. is serving as the sole placement agent for the public offering. The offering is being made under a registration statement on Form S-3 (File No. 333-282297) that the company reports was declared effective by the SEC on October 3, 2024. The press release notes that the securities may only be offered by means of the final prospectus supplement and accompanying base prospectus.

Sources: S1

Business context and device status

Glucotrack operates Lōkahi Therapeutics and, through a subsidiary, focuses on technologies for people with diabetes including a long-term implantable continuous blood glucose monitoring system. The company describes the Glucotrack CBGM as an Investigational Device limited by federal law to investigational use.

Sources: S1

Inference — why this may matter

If completed, the offering would provide additional gross capital resources reported as approximately $3,100,000 before fees and expenses, which may affect the company’s near-term funding runway and ability to support ongoing development activities. The reliance on a best-efforts structure and customary closing conditions means completion is not guaranteed.

Sources: S1

What remains uncertain

• The press release contains forward-looking statements and notes that the offering may not close when anticipated, or at all, if customary closing conditions are not satisfied. The company’s statements about expected proceeds and timing are issuer projections and are not independently verified in the source.
• The press release discloses aggregate gross proceeds 'before deducting placement agent fees and offering expenses' but does not quantify those fees or net proceeds.
• Descriptions of product programs and platform activity are issuer statements; clinical, regulatory, and commercial outcomes for the Glucotrack CBGM are not provided and the device remains described as investigational.